News
Hepatitis Foreningen

 
 
 

Page 5 of 13

  • Australian women's experiences of living with hepatitis C virus: results from a cross-sectional survey
  • Pegasys found superior to current hepatitis B treatments
  • Study shows 24 weeks of PegIntron combination therapy as effective as 48 weeks in genotype 2/3 hepatitis C patients
  • Pilot study of the relationship between histologic progression and hepatic
  • DEPRESSIVE SYMPTOMS DURING IFN-ALPHA/RIBAVIRIN THERAPY ARE ASSOCIATED WITH REDUCED VIRAL CLEARANCE IN PATIENTS WITH HEPATITIS C
  • Chronic hepatitis C: updated Swedish consensus.
  • Schering-Plough to Initiate First Head-to-Head Study of PEG-Intron Versus Pegasys for Chronic HCV Infection
  • "Hepatitis respects no borders".
  • Screening standards for infectious diseases in pregnancy
  • FDA Grants Marketing Approval to Schering-Plough's Rebetol for Treatment of Hepatitis C in Children
  • 24 Weeks of Therapy with Peginterferon Alfa Plus Ribavirin Is Sufficient for HCV Genotypes 2 and 3
  • Pegasys (peginterferon alfa-2a) Is More Effective Than Current Standard Therapy for Chronic Hepatitis B
  • Diagnosis of Acute Hepatitis C: Test for Anti-HCV or HCV-RNA?
  • Prevalence of Hepatitis A, Hepatitis B and HIV Among Hepatitis C Positive State Hospital Patients
  • Hepatitis C Drug Market to Grow from $2.5 Billion in 2002 to More Than $9 Billion in 2012

    • Go to page 1 2 3 4 5 6 7 8 9 10 11 12 13

    << Previous  Next >>